接口广告
摩熵化学
数据开放平台 数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-chloro-6-hydroxy-9-nitro-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid

中文名称
——
中文别名
——
英文名称
8-chloro-6-hydroxy-9-nitro-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
英文别名
——
8-chloro-6-hydroxy-9-nitro-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid化学式
CAS
——
化学式
C13H11ClN2O5
mdl
——
分子量
310.69
InChiKey
WGUAPOVFDKLQGB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    21
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    115
  • 氢给体数:
    3
  • 氢受体数:
    6

文献信息

  • Methods and compositions for the inhibition of Pin1
    申请人:Beth Israel Deaconess Medical Center, Inc.
    公开号:US10413548B2
    公开(公告)日:2019-09-17
    The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
    本发明的特点是抑制 Pin1 蛋白的组合物和方法,以及治疗以 Pin1 平升高为特征的疾病。
  • Methods and compositions for the inhibition of PIN1
    申请人:Beth Israel Deaconess Medical Center, Inc.
    公开号:US11129835B2
    公开(公告)日:2021-09-28
    The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
    本发明的特点是抑制 Pin1 蛋白的组合物和方法,以及治疗以 Pin1 平升高为特征的疾病。
  • METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1
    申请人:Beth Israel Deaconess Medical Center, Inc.
    公开号:US20150133442A1
    公开(公告)日:2015-05-14
    The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
  • ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS
    申请人:Beth Israel Deaconess Medical Center, Inc.
    公开号:US20180153934A1
    公开(公告)日:2018-06-07
    The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.
  • US9730941B2
    申请人:——
    公开号:US9730941B2
    公开(公告)日:2017-08-15
查看更多